Pharmacist Independent Prescribers An Urgent Need For India!.

http://ipa.medlineindia.com/members/barunhere/activity/3364
Dr. Barun Ranjan Sarkar PharmD. posted an update: 2 years, 3 months ago
Pharmacist Independent Prescribers An Urgent Need For India!.
The United Kingdom as always is the best reference point for our health sector since most of our structures and training of personnel were fashioned along the lines of our colonial masters. Pharmacist Independent Prescribers in the United Kingdom are pharmacists who have a number of years experience practicing in a clinical environment and have received added postgraduate training (usually from six to eighteen months) and are empowered to carry out prescribing duties.
A Pharmacist Independent Prescriber in the UK must be a registered pharmacist whose name is held on the membership register of the Royal Pharmaceutical Society of Great Britain (RPSGB), with an annotation signifying that the pharmacist has successfully completed an education and training programme accredited by the RPSGB and is qualified as an independent prescriber. Once qualified, Pharmacist Independent Prescribers are able to prescribe any licensed medicine for any medical condition within their competence. This only recognizes the fact that pharmacists as creators and producers of all drugs are in a unique position as their expertise in the use of drugs is absolutely incomparable.
The UK’s Department of Health’s working definition of independent prescribing is prescribing by a practitioner (e.g. doctor, dentist, pharmacist) responsible and accountable for the assessment of patients with undiagnosed or diagnosed conditions and for decisions about the clinical management required, including prescribing.
Aims of independent prescribing by pharmacists
According to the Department of health, it is the UK governments’ policy to extend prescribing responsibilities to nonmedical professions to:-
1. Improve patient care without compromising patient safety;
2. Make it easier for patients to get the medicines they need;
3. Increase patient choice in accessing medicines;
4. Make better use of the skills of health professionals;
5. Contribute to the introduction of more flexible team working across their National Health
Service (NHS).
Some Question & answer about Pharmacist Independent Prescribers
Q: What is independent prescribing?
A: Independent prescribing is prescribing by a practitioner eg. doctor, dentist, nurse, pharmacist or optometrist responsible and accountable for the assessment of patients with undiagnosed and diagnosed conditions and for decisions about the clinical management, including prescribing.
Q: What can Pharmacist Independent Prescribers prescribe?
A: Any medicine for any medical condition within their competence, with the current exception of controlled drugs.
Prescribing unlicensed medicines and ‘off-label’ / ‘off-license’ prescribing
Q: Can Pharmacist Independent Prescribers prescribe unlicensed medicines?
A: Yes, following changes in December 2009, Pharmacist Independent Prescribers can prescribe unlicensed medicines for their patients, on the same basis as doctors and provided that they are competent and take responsibility for doing so.
Q: Can Pharmacist Independent Prescribers prescribe ‘off-label’ or ‘off-license’?
A: Qualified Pharmacist Independent Prescribers can prescribe medicines ‘off-label’ or ‘off license’.
However, Pharmacist Independent Prescribers must take full clinical and professional responsibility for their prescribing and should only prescribe ‘off-label’ or ’off-license’ where it is best practice to do so.
Mixing of medicines
Q: Can Pharmacist Independent Prescribers mix medicines prior to administration?
A: Yes. Changes to medicines regulations came into effect from December 2009 that enable Pharmacist Independent Prescribers to mix medicines prior to administration, and direct others to mix.
Borderline substances
Q: Can Pharmacist Independent Prescribers prescribe borderline substances independently?
A: Yes, but DH guidance recommends that Pharmacist Independent Prescribers restrict their prescribing to the substances on the Advisory Committee on Borderline Substances approved list, in Part XV of the Drug Tariff.
Use of Botox® and Vistabel® in cosmetic procedures
Q: Can Pharmacist Independent Prescribers prescribe Botox® independently and administer it for use in cosmetic procedures?
A: Yes. A Pharmacist Independent Prescriber can legally prescribe and administer licensed parenteral medicines such as Botox® in cosmetic procedures on his or her own initiative.
However, the use of Botox for cosmetic treatment is outside the product’s licensed indications. Pharmacist Independent Prescribers may prescribe medicines independently for uses outside their licensed indications so called ‘off-licence’ or ‘off-label’. They must however, accept professional, clinical and legal responsibility for that prescribing, and should only prescribe ‘off-label’ / off-license’ where it is accepted clinical practice.
Q: Can Pharmacist Independent Prescribers prescribe Vistabel® independently and administer it for use in cosmetic procedures?
A: Yes. A Pharmacist Independent Prescriber can legally prescribe and administer licensed parenteral medicines such as Vistabel® in cosmetic procedures on his or her own initiative.
Q: Are pharmacists able to issue private prescriptions?
A: Pharmacist Independent Prescribers can issue private prescriptions for any medicine within their competence, with the current exception of controlled drugs.
Q: Are Pharmacist Independent Prescribers able to give directions to a non-prescriber for the administration of a medicine?
A: Yes. A qualified Pharmacist Independent Prescriber may give directions for the administration of any product they are legally allowed to prescribe ie a medicine for a condition within his/her competence. The prescribing pharmacist needs to be satisfied that the person to whom he or she gives the instructions is competent to administer the medicine concerned.
Q: Are pharmacists able to prescribe or supply blood or blood products on the NHS?
A: Blood, including the cellular elements that are packaged for use as ‘packed cells’ and platelets, is not considered to be a medicinal product and is therefore outside the ambit of the Medicines Act and its subsequent amending Regulations. The ‘prescribing’ of blood for a patient is not therefore appropriate for pharmacist independent prescribing or for supply under the terms of a Patient Group Direction (PGD). Pharmacists should discuss the current local policy regarding ordering of these products with their Trust’s haematology department. Consideration could be given to developing local guidelines for the ordering and supply of blood, based on the format of a PGD.
However, products derived from the plasma component of blood such as blood clotting factors, antibodies and albumin are considered to be medicinal products and are required to have marketing authorisations. These products may be prescribed by Pharmacist Independent Prescribers or as part of a supplementary prescribing arrangement. It may also be sensible to discuss any proposed prescribing with the Trust’s Haematology Department, in advance.
Prescription forms
Q: What prescription forms should Pharmacist Independent Prescribers use?
A: Further information on prescription forms, including the types of form and how to order supplies of these, is available in the Department of Health’s prescribing implementation guidance and via the NHS Business Services Authority website.
Improving patients’ access to medicines: A guide to implementing nurse and pharmacist independent prescribing within the NHS in England
NHS prescription services: Prescription forms (opens new window)
Training
Q: Who will decide which pharmacists are eligible to be trained as prescribers?
A: Pharmacists must first meet the eligibility criteria as determined by the Royal Pharmaceutical Society of Great Britain (RPSGB). Once these are met, it is a matter for local decision, in the light of local NHS need, benefit and circumstances. No pharmacists will be required to undertake training for prescribing unless they wish to do so. There also needs to be a local need for them to prescribe and for the service.
Q: Can pharmacists employed by prisons or charitable and private organisations outside the NHS undertake prescribing training?
A: Yes – pharmacists employed outside the NHS may also apply to undertake prescribing training. Pharmacists employed by non-NHS organisations and who provide the majority of their services to NHS patients can also be considered for SHA funded prescribing training from the Multi-Professional Education and Training (MPET) levy. Other non-NHS pharmacists will need to identify an alternative source of funding. They also need to have identified a medical supervisor who is willing to help with the ‘supervision in practice’ element of the course.
Community pharmacists and any other pharmacists employed by the independent sector, but who supply services to NHS organisations wishing to train to prescribe at NHS expense, will need to have the agreement of their local PCT or NHS Trust with whom they are contracted and have access to a prescribing budget, once qualified.
Q: Who bears legal and professional responsibility for the actions of pharmacist prescribers?
A: Pharmacist Independent Prescribers are professionally responsible for their own actions. They should therefore only prescribe in situations where they feel fully competent, using those medicines that they feel are effective for the patient and the condition being treated. Where a pharmacist is appropriately trained and qualified as an independent prescriber, and prescribes as part of his or her professional duties with the consent of the employer or local PCT, the employer may also be held vicariously responsible for the pharmacist’s actions. The Department’s guide to implementation of nurse and pharmacist independent prescribing, advises all independent prescribers to ensure that they have professional indemnity or insurance – for example through membership of a professional organisation or trade union.
The RPSGB Code of Ethics states that all pharmacists who own a pharmacy, superintendent pharmacists and pharmacists managers should ensure that all professional activities undertaken by them or under their control are covered by their professional indemnity or insurance. The standard on prescribing within the Code also says that pharmacists must only prescribe within the limits of their registration and must comply with statutory requirements applicable to their prescribing.
The above mentioned facts were from department of health government of united kingdom.
But my question is, if india can follow British pattern for medical education and practice then why not it is same for pharmaceutical education and practice (Pharmacist Independent Prescribers)?. As due to large population size, India is already lagging in doctor and population ratio!.
Therefore, I think the matter should be considered and necessary measures should be taken .
Barun Ranjan Sarkar
Reference:-

Nurturing the industry - Express Pharma Online

Nurturing the industry - Express Pharma Online



Industry associations bridge the gap between companies, policy makers and talent pools. A look at some of their initiatives to create a stronger connect between these stakeholders. By Usha Sharma
The Indian pharmaceutical industry has carved its niche in both the markets, domestic as well as international with its expertise in high end IT and cutting edge science technology. India has strong research and development (R&D) pipeline, maximum number of US FDA approved manufacturing sites outside the US, low R&D costs, innovative scientific manpower with low cost availability which has attracted multinational pharma companies to invest in India. cont.. above url...

ISMP AND FDA CAMPAIGN TO ELIMINATE USE OF ERROR-PRONE ABBREVIATIONS

http://www.ismp.org/Tools/abbreviations/default.asp

The Institute for Safe Medication Practices (ISMP) and the U.S. Food and Drug Administration (FDA) have launched anational education campaign to help eliminate one of the most common but preventable sources of medication errors—the use of ambiguous medical abbreviations.
Some abbreviations, symbols and dose designations are frequently misinterpreted and lead to mistakes that result in patient harm. The ISMP-FDA campaign seeks to promote safe practices and prevent serious and even potentially fatal mistakes when communicating medication orders.

cont... pls visit above url


Food and Drug Administration urges chemists to comply with Schedule H1 | The Asian Age

Food and Drug Administration urges chemists to comply with Schedule H1 | The Asian Age



Following the WHO’s latest report on the burgeoning problem of antibiotic resistance in southeast Asia, Maharashtra Food and Drug Administration (FDA) commissioner Mahesh Zagade has urged chemists to comply with Schedule H1 on an urgent basis.“For the past 30 to 40 years, chemists have not been following Schedule H and Schedule X that state that drugs are to be sold only when prescribed by a registered medical practitioner. Hence, the need to introduce Schedule H1 was felt by the Union health and family welfare ministry with new provisions. I do not want this carelessness to go on and resistance to rise further,” said Mr Zagade.
Schedule H1 to the Drugs and Cosmetics Act was introduced by the government of India early in March to check
indiscriminate use of antibiotics, anti-TB and some other drugs in the country. Schedule H1 includes 46 drugs for which chemists have to retain a copy of the prescription of every patient they sell them to. In addition, chemists have to maintain a separate register for these drugs, containing the name of the patient and details of the doctor who prescribed the drugs.
The register has to be kept for three years before being destroyed. Besides, the drugs would be sold only on
prescription.This amendment to the act was made in lieu of the increasing virus resistance to these drugs which are mainly third and fourth generation antibiotics, anti-TB and certain habit-forming drugs.“The resistance against these drugs is rising to horrifying levels and the main culprit is the medicines. Many drugs have been sold without prescription even when it was a crime under the Drugs and Cosmetics Act,” said Mr Zagade.
Many of the chemists across Maharashtra are yet to follow the newly-amended schedule H1 effective from March 1, 2014 due to lack of awareness and cumbersome record keeping. “We are neither aware of it nor have we received any circulars from the authorities. Though we do not sell any medicine without prescription, we are not maintaining any register for the ones we are selling,” said a pharmacist.

India misses key health targets, but shows improvement PTI | New Delhi | Published: Jul 18 2014, 17:24 IST

http://www.financialexpress.com/news/india-misses-key-health-targets-but-shows-improvement/1271237
SUMMARYJharkhand, Chhattisgarh, Arunachal Pradesh, Gujarat, Assam, Haryana, Madhya Pradesh and Rajasthan have TFR between 2.2 and 3.
TFR is, however, showing a decline nationally as it was 2.6 in 2008 and 2.5 in 2010.(Reuters)India is lagging considerably behind its key human development index targets, including population control, infant mortality rate (IMR) and maternal mortality rate (MFR), according to figures given by Health Minister Harsh Vardhan in Lok Sabha today.
The goals set by the government for IMR and MMR for 2010 were 30 per 1000 live births and 100 per 1 lakh live births repectively but it could achieve numbers of 42 and 178 only by 2012, falling way behind.
The total fertility rate (TFR) in 2012 was 2.4 while the target was 2.1 for 2010, Vardhan said. A TFR of 2.1 per woman is expected to make the population growth zero.
Though 23 states and UTs, including all four southern states, have already achieved replacement level fertility of 2.1 or less, the most populous state of UP and Bihar have TFR of 3.3 and 3.5 respectively, he said.
Jharkhand, Chhattisgarh, Arunachal Pradesh, Gujarat, Assam, Haryana, Madhya Pradesh and Rajasthan have TFR between 2.2 and 3.
TFR is, however, showing a decline nationally as it was 2.6 in 2008 and 2.5 in 2010.
India has also shown improvement on IMR and MMR indicators as they were 53 and 212 in 2008 and 2007-09 respectively, according to official figures.
Vardhan said the country may reach its Millennium Development Goals, set up by the United Nations, of reaching under-five mortality rate of 42 in 2015 if the current trend of annual decline persists. The rate was 126 in 1990.
The MDG target for maternal mortality rate is 140 in 2015 and India is likely to reach 141 with its current rate.

Indian minister backs calls to end health sector corruption

NEW DELHI, July 18 Fri Jul 18, 2014 6:28pm IST

(Reuters) - India's healthcare system is riddled with corruption and the national drug approvals agency is a "snakepit of vested interests", the health minister has said, backing a rising tide of criticism by doctors of unethical practices.
Health Minister Harsh Vardhan's remarks came after leading doctors and advocacy groups joined hands in a bid to eradicate corruption from India's $74 billion healthcare industry, forming anti-graft panels at hospitals and writing open letters to Prime Minister Narendra Modi's new government.
"I am more aware than anybody else of the corruption that is eating into the entrails of every aspect of governance, including the health system," Vardhan, himself a doctor, said in an interview with Friday's Indian Express newspaper. "I have inherited a poisoned chalice."
Practices such as taking kickbacks for referring patients to a particular test centre or receiving gifts from companies for prescribing their drugs are widespread in the medical profession.
India this week capped the prices of more than 100 drugs used to treat diseases ranging from diabetes to HIV, in a move likely to hit the profit margins of drug firms.
Though the industry is growing at 15 percent annually, according to consulting firm PwC, public spending on healthcare has stagnated at about 1 percent of gross domestic product for years. That compares to 3 percent in China and 8.3 percent in the United States, according to a World Bank database for 2012.
The anti-corruption debate gained momentum after Australian doctor David Berger wrote a column for the British Medical Journal (BMJ) in May, describing his encounters with corrupt professionals when he worked as a volunteer at a charitable hospital in the Himalayas.
Several eminent Indian doctors and editors of the journal followed up with their own articles in late June, exposing the sleaze problem faced by patients and the healthcare industry.
GROWING SUPPORT
Berger's column, titled "Corruption ruins the doctor-patient relationship in India", said kickbacks and bribes oil every part of the healthcare apparatus.
"It is no surprise that investigations and procedures are abused as a means of milking patients," Berger wrote.
The column made 76-year-old Samiran Nundy, one of India's leading gastroenterologists, feel "ashamed", forcing him to put his own experiences into writing after working in the public and private sector for almost four decades.
Sir Ganga Ram Hospital, a leading multi-speciality hospital in the capital, has formed a committee for ethical practices under Nundy, listing new guidelines for its doctors to curb corruption.
"Many doctors may be opposed to having this body because they think it will interfere with their practice," Nundy told Reuters.
The All India Institute of Medical Sciences in New Delhi has launched an initiative called 'Society for Less Investigative Medicine' to deter doctors from advising patients to take unnecessary medical tests.
Advocacy group People's Health Movement has written an open letter to the health minister, seeking his personal intervention to eliminate corruption from India's private health sector.
The response to articles has overwhelmed BMJ's India editor Anita Jain, who said the journal will continue to focus on writing editorials to raise awareness of such practices.
"This (new panel) is for the next generation. Merit should be rewarded, not crookedness," Nundy said. (Editing by Douglas Busvine and Robert Birsel)

India largest user antibiotic meant for multi-drug resistant bacteria, says report

http://www.firstpost.com/living/india-largest-user-antibiotic-meant-multi-drug-resistant-bacteria-says-report-1619849.html
A recent study has shown that India is the largest user of an antibiotic called carbapenems meant only as a "last resort drug" for fatal multi-drug resistant bacteria.
The Telegraph reports"The study, described as the world’s largest analysis of antibiotics consumption, has found that retail sales of carbapenems in India jumped from 0.15 standard units per 1,000 population in 2005 to nearly 3.8 standard units per 1,000 population in 2010, one of the steepest gradients in the world."
Ramanan Laxminarayanan, a health economist and vice-president of research at the Public Health Foundation of India, New Delhi told The Telegraph"Carbapenems are currently considered the most powerful available antibiotics against multi-drug resistant bacterial infections that are typically seen among patients admitted in intensive care units. The carbapenems are seen as “last-resort” antibiotics."
Representational image. AFP
Representational image. AFP
And this is not the only alarming statistic regarding India and antibiotics.
India has also emerged as the world's overall largest consumer of antibiotics followed by China and the US, according to a study by Princeton University researchers who have conducted a broad assessment of antibiotic consumption around the world.
The study, "Global Trends in Antibiotic Consumption, 2000-2010," which quantifies the growing alarm surrounding antibiotic-resistant pathogens, and a loss of efficacy among antibiotics used to combat the most common illnesses, found that worldwide antibiotic use has risen a staggering 36 percent over those 10 years, with five countries -- Brazil, Russia, India, China and South Africa (BRICS) - responsible for more than three-quarters of that surge.
Among the 16 groups of antibiotics studied, cephalosporins, broad-spectrum penicillins and fluoroquinolones accounted for more than half of that increase, with consumption rising 55 percent from 2000 to 2010.
In India, the problem is most widely seen in cases of Tuberculosis, which the country has been trying to fight on a war footing for decades.
Despite a concerted effort on the part of government and health authorities however, cases of TB have only been rising, with new, stronger and drug resistant strains of the fatal disease constantly evolving.
And while the abuse of strong antibiotics may be one of the reasons behind the mutation of the virus, it turns out that premature discontinuation of a course of antibiotics is also an issue.
An editorial in The Financial Express points out"India's success with TB control, despite $182 million being pumped into the National TB control Programme in 2013 alone, has been marginal because of the lapses in treatment, especially with patients failing to follow through with the due course of medication. Given how the course of treatment is long, a bulk of the patients, usually from the lower economic sections, often stop medication at the first sign of recovery."
This is not the case only with tuberculosis. The tendency to stop a course of antibiotics before the prescribed duration is a common trait among Indians, whether they are fighting TB, fever or the common cold.
Researchers in the Princeton study had also noted that antibiotic use is not being effectively monitored by health officials, from doctors to hospital workers to clinicians. Consequently, antibiotic use is both rampant and less targeted. That reality is driving antibiotic resistance up at an unprecedented rate, researchers said.
As a means of combating this problem, the government had made it mandatory for retail pharmacists to sell antibiotics only when the patient had a prescription. It had also suggested that a government executive audit the sales.
However, The Telegraph reports, "But representatives of retail chemists in India had themselves earlier this year expressed concerns that the new rules are impractical. “In this country, many patients can’t afford to pay doctors’ fees but need antibiotics,” a representative of the retail pharmacists in Delhi had said earlier this year."

India caps price of 108 more medicines; drugmakers to take hit

By Zeba Siddiqui
MUMBAI (Reuters) - India has capped the prices of more than 100 drugs used to treat diseases ranging from diabetes to HIV, a move likely to hit the profit margins of drug firms such as Sanofi SA, Abbott Laboratories and Ranbaxy Laboratories Ltd.
The drug pricing regulator's decision, aimed at improving affordability, was slammed by the drugmakers in India, where prices of generic drugs sold are already low compared with international markets.
India, an emerging market for drugmakers, last year raised the number of drugs that are subject to price control to cover up to 30 percent of the total medicines sold in the country, according to industry officials.
"While we appreciate the government's intent to improve affordability ... the manner and method in which this unilateral decision has been taken, is untenable," Sanofi India's Managing Director Shailesh Ayyangar said on Monday.
"We are evaluating the impact of this order on our ability to continue offering our products with the same value proposition," he said, adding the decision has "shocked and disappointed" the pharmaceutical industry.
The notice by the National Pharmaceutical Pricing Authority (NPPA), published on its website on Friday, coincides with moves by the health ministry to widen the list of essential medicines that will be subject to a price cap, people familiar with the matter said last month.
The move is aimed at making medicines more affordable in a country where 70 percent of the population lives on less than $2 a day. More than four-fifths of India's 1.2 billion also have no health insurance.
The new price caps took effect on July 11, an NPPA official said. Injeti Srinivas, who took charge as NPPA's chairman in June, was not immediately available for comment.
"This is very unexpected and unfortunate. One would expect them to proceed with revising the list of essential medicines, but this has caught people by surprise," said Sujay Shetty, PwC's India leader of pharmaceuticals and life sciences.
"They should have done a little more thinking and consultations. This way, they're going to drive out the better players from the market, and the quality of drugs could be compromised."
Shares in Sanofi India closed down 10 percent at 2,923.05 rupees on Monday and Ranbaxy fell 0.4 percent to 553.70 rupees, while the main Mumbai market index ended little changed from its previous close.
PUBLIC INTEREST
Analysts at Nomura on Sunday named Sanofi India, the Indian unit of French drugmaker Sanofi, Abbott Healthcare Private Ltd, a unit of U.S.-based Abbott Laboratories, and local firm Ranbaxy as among companies that will be most impacted by the price cap.
Abbott and Ranbaxy did not respond to requests for comment.
"Though the impact is limited, the move by the NPPA has increased the risk of additional controls in the future," Nomura analysts Saion Mukherjee and Lalit Kumar wrote in the report.
The drug pricing regulator invoked a rarely-used provision that gives the agency the right to fix the prices of any drug "in extraordinary circumstances, if it considers necessary so to do in public interest".
A spokesman for Dr. Reddy's Laboratories Ltd, India's second-largest drugmaker by sales, said the company was assessing its next step, but does not expect the price caps to have a material impact on its financial results.
"At an industry level, there may be some discussion to see whether one can challenge this," he said, but added that the regulator's decision to invoke the "public interest" provision would make the options limited.
Drugs included in the price cap list are "fairly meaningful molecules," so companies would not exit the market, said Arvind Bothra, an analyst at brokerage Religare Capital.
"They will take the price cut, increase their volumes, and move on. The bigger problem for the industry is the uncertainty this ad-hoc expansion brings."
(Editing by Louise Heavens)

The National Pharmaceutical Pricing Authority has fixed / revised the prices in respect of 39 formulation packs both ceiling and retail price 12th July, 2014

http://www.nppaindia.nic.in/wh-new-2014/wh-new-48-2014.html

Dated : 12th July, 2014

The National Pharmaceutical Pricing Authority has fixed / revised the prices in respect of 39 formulation packs both ceiling and retail price and one Withdraw notification regarding S.O. No. 1784(E) dated 10.7.2014 relating Ciprofloxacin Hcl under DPCO, 2013 in related Notification / order dated 10.7.2014 and 11.7.2014 is given below :-
For details please click the following:

Copies of Gazette Notifications for Ceiling Prices/retail price under DPCO, 2013
 
S.NoS.O.NoDateFormulation based on bulk drugs
1.1780(E)10-7-2014Pyrimethamine
2.1781(E)10-7-2014Actinomycin D
3.1782(E)10-7-2014Codeine Phosphate
4.1783(E)10-7-2014Sodium Nitrate
5.1784(E)10-7-2014Ciprofloxacin Hcl
6.1785(E)10-7-2014Phenobarbitone
7.1786(E)10-7-2014Atorvastatin
8.1787(E)10-7-2014Heparin Sodium
9.1788(E)10-7-2014Tramadol
10.1789(E)10-7-2014Pantoprazole
11.1790(E)10-7-2014Albendazole
12.1791(E)10-7-2014Condoms
13.1792(E)10-7-2014Calamine Lotion
14.1793(E)10-7-2014Metformin Hydrochloride, Glimepiride, Pioglitazone , Voglibose
15.1794(E)10-7-2014Esomeprazole, Domperidone
16.1795(E)10-7-2014Cefixime
17.1796(E)10-7-2014Artesunate
18.1797(E)10-7-2014Desogestrel, Ethinylestradiol
19.1798(E)10-7-2014Glimepiride, Voglibose, Metformin Hydrochloride
20.1799(E)10-7-2014Glimepiride, Voglibose, Metformin HCL
21.1800(E)10-7-2014Atorvastatin & Clopidogrel
22.1801(E)10-7-2014Nadifloxacin, Mometasone Furoate, Miconazole Nitrate
23.1802(E)10-7-2014Paracetamol, Mefenamic Acid
24.1803(E)10-7-2014Cefixime, Ofloxacin
25.1804(E)10-7-2014Telmisartan, Amlodipine
26.1805(E)10-7-2014Acetaminophen, Tramadol Hydrochloride
27.1806(E)10-7-2014Diclofenac Sodium
28.1807(E)10-7-2014Amlodipine, Telmisartan, Hydrochlorothiazide
29.1808(E)10-7-2014Bromhexine Hydrochloride, Phenylephrine Hydrochloride, Guaiphensin, Chlorpheniramine Maleate, Paracetamol
30.1809(E)10-7-2014Trypsin Chymotrypsin, Diclofenac Potassium
31.1810(E)10-7-2014Ofloxcacin, Ornidazole, Paracetamol, Mefenamic Acid
32.1811(E)10-7-2014Atorvastatin with Vitamin D3
33.1812(E)10-7-2014Cefixime with Linezolid
34.1813(E)10-7-2014Oxaliplatin
35.1823(E)10-7-2014Withdraw the notification S.O. NO. 1784(E) dated 10.7.2014 reg. Ciprofloxacin HCl

India likely to extend price caps to more drugs: Report - Khaleej Times

India likely to extend price caps to more drugs: Report - Khaleej Times

Budget 2014: Pharma sector left ailing for remedial measures

Finance Minister presented the much awaited maiden Budget of the new BJP-led government yesterday. Given the prevailing situation of low growth combined with high inflation and a large fiscal deficit, the budget was anticipated with a sense of hope and aspiration, the belief that it would ring in achche din, albeit in the long run. While the cash-strapped Government was not expected to announce massive sops for industry, it was nevertheless hoped that the Budget would provide directional clarity .. 

NPPA seeks states' participation to keep drug prices under control

NEW DELHI: The drug pricing regulator has urged state governments to identify expensive and most commonly used drugs for diseases prevalent in their regions, which they think should be brought under price control in public interest. 

This comes close on the heels of National Pharma Pricing Authority's (NPPA) plans to lower prices of expensive medicines used for select therapeutic categories such as cancer, HIV, diabetes, cardiovascular diseases, malaria and tuberculosis, as reported ..